ValorQ4, 24Q1, 25Q2, 25Q3, 25Q4, 25TTMSelling/general/admin expenses3.59 M3.96 M4.93 M4.8 M3.9 M17.6 MResearch & development12.23 M11.81 M15.38 M22.13 M10.89 M60.22 MOperating income-15.82 M-15.77 M-20.31 M-26.75 M-14.8 M-77.63 MNon-Operating Income, Total852 K892 K781 K999 K832 K3.5 MInterest expense, net of interest capitalized——————Non-Operating Income, excl. Interest Expenses852 K892 K781 K999 K832 K3.5 MUnusual income/expense——————Pretax income-64.02 M-14.88 M-19.53 M-25.75 M-74.12 M-134.28 MEquity in earnings——————Taxes0———3.51 M—Non-controlling/minority interest-1 000-1 000-1 000-2 000-1 000-5 000After tax other income/expense——————Net income before discontinued operations-14.97 M-14.88 M-19.53 M-25.74 M-13.96 M-74.12 MDiscontinued operations——————Net income-14.97 M-14.88 M-19.53 M-25.74 M-13.96 M-74.12 MDilution adjustment——————Preferred dividends——————Diluted net income available to common stockholders-14.97 M-14.88 M-19.53 M-25.74 M-13.96 M-74.12 MBasic earnings per share (Basic EPS)-0.17-0.17-0.22-0.26-0.15-0.8Diluted earnings per share (Diluted EPS)-0.17-0.17-0.22-0.26-0.15-0.8Average basic shares outstanding74.26 M86.49 M90.12 M97.15 M92.99 M366.74 MDiluted shares outstanding74.26 M86.49 M90.12 M97.15 M92.99 M366.74 MEBITDA-15.64 M-15.61 M-20.15 M-26.58 M-14.63 M-76.96 MEBIT-15.82 M-15.77 M-20.31 M-26.75 M-14.8 M-77.63 MCost of revenue——————Other cost of goods sold——————Depreciation & amortization (cash flow)175 K167 K166 K165 K166 K664 K
aTyr Pharma Inc
aTyr Pharma is a public biotherapeutics company that is focused on researching the extracellular functionality and signaling pathways of tRNA synthetases.
The company's lead product candidate, ATYR1923, is a selective modulator of Neuropilin-2 that downregulates both the innate and adaptive immune responses in inflammatory disease states. aTyr is developing ATYR1923 as a potential disease-modifying therapy for patients with interstitial lung disease, a group of rare immune-mediated disorders that cause progressive fibrosis of the lung interstitium and remain a high unmet medical need. ATYR1923 is currently being investigated in a clinical trial in pulmonary sarcoidosis patients.
The company was founded in 2005 and is headquartered in San Diego, California, and led by CEO Sanjay S. Shukla.